Cemsidomide vs TQB3820

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: Cereblon E3 ubiquitin-ligase · full Multiple Myeloma pipeline

Cemsidomide

Developed by C4 Therapeutics, Inc.

Phase 2 in Multiple Myelomasmall molecule (targeted protein degrader / cereblon E3 ligase modulator)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2028 · NCT07280013 (registry estimate)

No aligned efficacy figure on record for this race.

TQB3820

Developed by Sino Biopharmaceutical

small molecule
Weak signal

NCT05020639 · Phase 1 · status unknown

This is a single-arm, open-label, non-randomized dose-escalation study designed to determine a tolerable dose rather than to test clinical benefit, with no comparator arm and no blinding. Results have not yet been posted. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)

No aligned efficacy figure on record for this race.

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCemsidomideTQB3820
PFS, median—Not reported—Not reported
OS, median—Not reported—Not reported
ORR—Not reported—Not reported
VGPR or better—Not reported—Not reported
MRD negativity—Not reported—Not reported

PFS, median

Cemsidomide
—Not reported
TQB3820
—Not reported

OS, median

Cemsidomide
—Not reported
TQB3820
—Not reported

ORR

Cemsidomide
—Not reported
TQB3820
—Not reported

VGPR or better

Cemsidomide
—Not reported
TQB3820
—Not reported

MRD negativity

Cemsidomide
—Not reported
TQB3820
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Cemsidomide: no structured comparison results are available for Multiple Myeloma.

TQB3820: no structured comparison results are available for Multiple Myeloma.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cemsidomide's landscape · TQB3820's landscape